Bryant Furlow is a contract medical journalist for the Haymarket Medical Network. He holds a bachelor of science in biology (summa cum laude) from the University of New Mexico. He covers radiation oncology, immunotherapy, tumor biology, clinical research, and health care policy. Prior to becoming a contributor to Haymarket Media in 2010, Bryant was a newspaper reporter in New Mexico, where he won awards for public health and investigative journalism. He also reports for The Lancet Oncology news desk.
Second-line treatment with axitinib showed superior PFS but not OS compared with sorafenib in metastatic renal cell carcinoma previously treated with cytokines, according to updated tiral results reported at the 2012 American Society of Clinical Oncology Annual Meeting.
Single-agent carfilzomib is efficacious in patients with relapsed and double-refractory/intolerant multiple myeloma, according to updatedtrial results presented at the 2012 American Association of Clinical Oncology Annual Meeting.
Nimotuzumab does not improve survival among newly diagnosed glioblastoma patients when added to standard temozolomide chemoradiotherapy, but warrants further study among patients with MGMT nonmethylated glioblastoma, according to a randomized multicenter phase 3 study reported at the 2012 American Society of Clinical Oncology Annual Meeting.